ArticleNature structural & molecular biology2026
Promoter reinforcement supports transcriptional resilience in drug-resistant cancer.
Article in Nature structural & molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In mammalian cells, gene-distal regulatory elements enable long-range gene regulation and support cell-type-specific transcriptional programs. This regulatory architecture is frequently perturbed in cancer, particularly when oncogenic transcription factors are targeted therapeutically. However, how cancer cells adapt under such selective pressure has remained poorly understood. Here we show that mesothelioma cells dependent on the oncogenic TEAD family of transcription factors acquire resistance to a pan-TEAD inhibitor. Such resistance is accompanied by a promoter-centric regulatory mechanism, a process we term promoter reinforcement, to sustain gene expression following TEAD inhibition. Using base-pair-resolution Micro Capture-C on a set of TEAD target genes, we find that regulatory element-promoter interactions are weakened or lost in resistant cells, even as promoter activity and gene expression recover in the context of partial epigenetic restoration. Mechanistically, resistance-induced transcription factors show promoter-biased localization and can increase promoter activity, whereas distal regulatory element function can become dispensable. Together, these findings identify promoter reinforcement as a locus-specific compensatory response that supports transcriptional resilience under TEAD inhibition, indicating promoter-associated vulnerabilities in drug-resistant cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.